Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.
about
The role of HPV in head and neck cancer and review of the HPV vaccineCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesThe prophylactic role for the human papillomavirus quadrivalent vaccine in males.Association of human papillomavirus-related knowledge, attitudes, and beliefs with HIV status: a national study of gay men.Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girlsExamining future adolescent human papillomavirus vaccine uptake, with and without a school mandate.A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.The impact of HPV female immunization in Italy: model based predictions.Global challenges of implementing human papillomavirus vaccines.Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in ChinaDealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.Potential benefits of second-generation human papillomavirus vaccines.The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam.Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: updated review.A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.Cost–effectiveness of catch-up programs in human papillomavirus vaccination.Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region.The cost effectiveness of human papillomavirus vaccines: a systematic review.Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.Value for money from HPV vaccination and cervical screening.The sexual ethics of HPV vaccination for boys.Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.To model or not to model: lessons from two vaccinations.Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14 year old girls against human papillomavirus.Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus.Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks
P2860
Q24630128-B1FBAF55-4AB1-472C-A26F-BB9F88B63D4FQ24655328-B6ED3DE3-19C5-4819-83D6-E032B65665C4Q33158795-D4460C44-9C69-4B46-848B-674D855C210EQ33624552-BB5F8AF8-F5D8-46C4-A8A9-4A24EE3015CFQ33898840-8CA3D72B-14CF-45BE-92DF-A7AFC7F6C95EQ33992093-AB5957AC-7060-4254-8790-CDC2F08726AFQ34072409-A6FC3AF6-2EFC-457E-A107-2355FEC50FC6Q34733919-EB3CB44B-CAFF-4F7D-B2B6-AA2F3AD59D02Q35117850-2B144877-FCB5-4140-BCC6-5AC9DFAE9095Q35128768-C7017074-CA24-4FFA-A271-AC231BF25078Q35779425-B8C64E78-593F-4D9C-B454-E1808A27C556Q35865134-F4D04387-6308-4664-9DEE-2E962442C22EQ35937679-FD918C7C-CA93-42B8-9805-AE6F4E5EB2CAQ36322923-FC7EF89D-201E-4D97-830E-7B55CE93F988Q36371450-69881826-6BFB-4862-8551-DAE06B626B44Q36380862-C47A2191-192D-470E-8ACB-45A180AF9327Q37016576-83DD695C-3708-470D-99AB-55027B3AC8E4Q37082469-C7D04869-4E9E-4D2F-9752-6FFFA03B2B40Q37251638-6C2A0E81-9508-4484-9C28-F97CE52F7D1EQ37694836-ED632A12-1554-47A0-8F5C-914C179D7574Q37798010-3D6AEC28-33A9-4240-A18C-9F75A30B497DQ37839828-BE951D17-DBBA-4178-98F8-5D2FDCC38569Q37977880-F83FAB26-69A6-4224-A352-E084DA875FF6Q37993109-3115667B-C4DD-407E-9962-509C94325607Q38027575-B05AD558-F3F7-43E0-9FDB-A97952A33607Q38255277-04733941-E37E-4517-991B-DAFAC2988171Q38284334-A4937E6C-80FD-430E-941D-3535507278ABQ38549643-91B28056-99B1-417A-B7FF-127398D9CB7BQ38803895-3401A239-CE8B-4E6A-8404-97524C1D7E2DQ39595847-2A95F4CA-8CF2-49BD-A831-3B941C36906DQ42252840-827E85B5-0823-4CD3-9EE0-9A1912B45267Q48030944-BC1D60CC-9BD5-4B01-920A-986597169D5EQ48703612-C0C032EF-CC1A-4988-914C-5B972AF4D6BFQ49990618-73902557-DBD8-4155-9250-66359DCAAB21Q51325275-66D0D377-66C9-4DF6-837F-76F8A3E3AA97Q53290879-EB0A033B-D507-438B-A568-62CC05CCBE8BQ58763799-ED9E331D-3BD6-475F-A772-338BA2D9975C
P2860
Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effectiveness and cost effecti ...... vaccine: a systematic review.
@ast
Effectiveness and cost effecti ...... vaccine: a systematic review.
@en
Effectiveness and cost effecti ...... vaccine: a systematic review.
@nl
type
label
Effectiveness and cost effecti ...... vaccine: a systematic review.
@ast
Effectiveness and cost effecti ...... vaccine: a systematic review.
@en
Effectiveness and cost effecti ...... vaccine: a systematic review.
@nl
prefLabel
Effectiveness and cost effecti ...... vaccine: a systematic review.
@ast
Effectiveness and cost effecti ...... vaccine: a systematic review.
@en
Effectiveness and cost effecti ...... vaccine: a systematic review.
@nl
P2093
P2860
P1433
P1476
Effectiveness and cost effecti ...... vaccine: a systematic review.
@en
P2093
Bridgette Oteng
Carlo Marra
Karine Cloutier
P2860
P304
P356
10.2165/00019053-200927020-00004
P577
2009-01-01T00:00:00Z
P6179
1020988473